The $9 Microcap That's "Worth" $31 a Share

In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

The announcement caught my eye for several reasons...

  1. PAUL G. | September 26, 2016

    What is Troven stock going to do.

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK